Drugs / NIDANILIMAB
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04990037 | Jul 2021 → May 2023 | pancreatic ductal adenocarcinoma | Cantargia AB | Completed | No outcome recorded |
| Phase 1 | NCT04452214 | Sep 2020 → Jun 2023 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, urothelial carcinoma | Cantargia AB | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07281716 | Dec 2025 → Dec 2028 expected | colorectal carcinoma | Dan Feng | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06548230 | Mar 2025 → Dec 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05181462 | Jan 2022 → Apr 2026 | triple-negative breast carcinoma | Cantargia AB | Completed | No outcome recorded |
| Phase 1/2 | NCT05116891 | Sep 2021 → Jun 2023 | biliary tract cancer, colorectal cancer, non-small cell lung carcinoma | Cantargia AB | Completed | No outcome recorded |
| Phase 1/2 | NCT03267316 | Sep 2017 → Mar 2024 | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, triple-negative breast carcinoma | Cantargia AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07284485 | May 2026 → Dec 2027 expected | — | Robert Samstein | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIDANILIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095365 ↗ |
| Known as | CAN04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990037 ↗ |
| Known as | nadunolimab | “Nadunolimab is an IL1RAP (IL-1 receptor accessory protein)-targeting antibody that blocks IL-1α/IL-1β signaling and has enhanced antibody-dependent cellular cytotoxicity.” PMID 40310569 ↗ May 20256“Nadunolimab, a fully humanized antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody, targets IL1RAP and blocks IL-1α/IL-1β signaling.” PMID 40680438 ↗ Jul 2025 “CAN04 (nadunolimab)” NCT05116891 ↗ |
| Action | Inhibit | “Nadunolimab, a fully humanized antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody, targets IL1RAP and blocks IL-1α/IL-1β signaling.” PMID 40680438 ↗ Jul 2025 |
| Modality | Monoclonal antibody | “CAN04 is a first-in-class fully humanized and ADCC enhanced monoclonal antibody, targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP).” NCT03267316 ↗ |
| Route | Intravenous | “A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.” NCT03267316 ↗ |
| Target | IL1RAP | “CAN04 is a first-in-class fully humanized and ADCC enhanced monoclonal antibody, targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP).” NCT03267316 ↗ |